DK0804584T3 - Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler - Google Patents

Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler

Info

Publication number
DK0804584T3
DK0804584T3 DK95936537T DK95936537T DK0804584T3 DK 0804584 T3 DK0804584 T3 DK 0804584T3 DK 95936537 T DK95936537 T DK 95936537T DK 95936537 T DK95936537 T DK 95936537T DK 0804584 T3 DK0804584 T3 DK 0804584T3
Authority
DK
Denmark
Prior art keywords
sequences
prophylactic
therapeutic
hepatitis
diagnostic agents
Prior art date
Application number
DK95936537T
Other languages
Danish (da)
English (en)
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0804584(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of DK0804584T3 publication Critical patent/DK0804584T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK95936537T 1994-10-21 1995-10-23 Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler DK0804584T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP95870076 1995-06-28
PCT/EP1995/004155 WO1996013590A2 (en) 1994-10-21 1995-10-23 New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents

Publications (1)

Publication Number Publication Date
DK0804584T3 true DK0804584T3 (da) 2002-09-23

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95936537T DK0804584T3 (da) 1994-10-21 1995-10-23 Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler

Country Status (12)

Country Link
US (2) US7129337B1 (de)
EP (2) EP0804584B2 (de)
JP (2) JPH10507643A (de)
AT (1) ATE218617T1 (de)
AU (1) AU702436B2 (de)
BR (1) BR9509421A (de)
CA (1) CA2201703A1 (de)
DE (1) DE69526973T3 (de)
DK (1) DK0804584T3 (de)
ES (1) ES2176342T5 (de)
PT (1) PT804584E (de)
WO (1) WO1996013590A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
AU751362B2 (en) 1998-04-17 2002-08-15 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents
DE19980730D2 (de) * 1998-04-28 2001-05-10 Wolfgang Bergter Radioimmunpharmaka zur Therapie der Hepatitis C
EP1555270A1 (de) * 1998-06-24 2005-07-20 Innogenetics N.V. HCV NS3 Proteine und ihre Nukleinsaüre
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
ATE375804T1 (de) * 2000-08-17 2007-11-15 Tripep Ab Ribavirin-enthaltende vakzine
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
ES2596753T3 (es) * 2003-08-29 2017-01-11 Fujirebio Europe N.V. Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
JP5138230B2 (ja) 2004-01-07 2013-02-06 サード・ウェーブ・テクノロジーズ・インク Ｃ型肝炎ウイルスの遺伝子型の決定方法
RU2267496C2 (ru) 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
EP1888751A2 (de) * 2005-05-25 2008-02-20 Tripep Ab Nichtstrukturelles ns3/4a-fusionsgen des hepatitis-c-virus
US7919242B2 (en) 2005-06-30 2011-04-05 Roche Molecular Systems, Inc. Light emission modifiers and their uses in nucleic acid detection, amplification and analysis
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
TR201802814T4 (tr) 2006-07-14 2018-03-21 Ac Immune Sa Amiloid betaya karşı insanlaştırılmış antikor.
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
KR101500017B1 (ko) 2006-08-25 2015-03-09 더 맥파레인 버넷 인스티튜트 포 메디칼 리서치 앤드 퍼블릭 헬스 리미티드 재조합 ｈｃｖ ｅ2 당단백질
EP2527474A1 (de) 2006-10-20 2012-11-28 Innogenetics N.V. Verfahren zur Analyse von Sequenzvariationen innerhalb des HCV-NS3/4A-Genombereichs
US20090325145A1 (en) 2006-10-20 2009-12-31 Erwin Sablon Methodology for analysis of sequence variations within the hcv ns5b genomic region
EP2108644B1 (de) 2006-11-24 2016-07-20 AC Immune S.A. N-(Methyl)-pyridin-2-amin-Derivate zur Behandlung von Krankheiten, die mit Amyloid oder amyloidartigen Proteinen zusammenhängen
AU2008267037B2 (en) 2007-06-12 2014-08-07 Ac Immune S.A. Monoclonal anti beta amyloid antibody
SG182192A1 (en) 2007-06-12 2012-07-30 Ac Immune Sa Humanized antibodies to amyloid beta
EP2236624B1 (de) * 2007-08-09 2012-11-07 Federalnoe Gosudarstvennoe Byudzhetnoe Uchrezhdenie Nauki Institut Molekulyarnoi Biologi Im. V.A. Engelgardta Rossiiskoi Akademii Nauk Verfahren zur identifizierung des genotyps und subtyps von hepatitis-c-virus auf einem biologischen mikrochip
EP2185195A2 (de) 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
SG178809A1 (en) 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
EP2311823A1 (de) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridinverbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloidproteinen oder zur Behandlung von Augenkrankheiten
EP2377860A1 (de) 2010-04-16 2011-10-19 AC Immune S.A. Neuartige Verbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloid- oder amyloidähnlichen Proteinen
AU2011239966B2 (en) 2010-04-16 2014-05-08 Ac Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
MX341369B (es) 2010-07-30 2016-08-17 Genentech Inc * Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
JP6371526B2 (ja) 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
CA2813833C (en) 2010-10-26 2020-09-22 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
BR112014008202B1 (pt) 2011-10-07 2022-01-04 Ac Immune S.A. Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção da formação de um complexo imunológico, método de detecção post­mortem de multimêros do fosfo-tau, kits de teste, linhagem celular isolada e método de detecção de multimêros de fosfo-tau
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
BR112015004022B1 (pt) 2012-08-31 2023-04-25 Sutro Biopharma, Inc Aminoácidos modificados compreendendo um grupo azido
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EP2994754B1 (de) * 2013-05-10 2018-07-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Zusammensetzungen und verfahren zur simultanen detektion des hcv antigens bzw. antikörpers
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
PH12016500425B1 (en) 2013-09-05 2022-07-29 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
JP7274259B2 (ja) 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
US11098107B2 (en) 2016-06-15 2021-08-24 Sutro Biopharma, Inc. Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
EP4114852A1 (de) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antikörper mit stellenspezifischen glutamin-tags, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung
WO2021224432A1 (en) 2020-05-06 2021-11-11 Ab2 Bio Sa Il-18 binding protein (il-18bp) in respiratory diseases
EP3943097A1 (de) 2020-07-24 2022-01-26 AB2 Bio SA Car-t-zelltherapie
US20250179131A1 (en) 2022-03-04 2025-06-05 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2656995B2 (ja) 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
CA2065287C (en) 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
AT400724B (de) 1989-12-18 1996-03-25 Wellcome Found Virales polypeptid
NZ238681A (en) 1990-06-25 1992-03-26 Univ Osaka Res Found Non-a, non-b hepatitis virus particles and their production
CA2108466C (en) 1991-05-08 2007-07-10 Tai-An Cha Hcv genomic sequences for diagnostics and therapeutics
ES2188583T3 (es) * 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
JPH06511149A (ja) 1991-09-13 1994-12-15 カイロン　コーポレイション 免疫反応性ｃ型肝炎ウイルスのポリペプチド組成物
EP0610436B9 (de) 1991-11-21 2003-03-26 Common Services Agency Detektion des Hepatis-C Virus.
AU688323B2 (en) * 1993-04-27 1998-03-12 N.V. Innogenetics S.A. New sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
AU3844095A (en) 1996-05-23
EP0804584A1 (de) 1997-11-05
EP1076092A2 (de) 2001-02-14
DE69526973D1 (de) 2002-07-11
US6974864B2 (en) 2005-12-13
EP0804584B1 (de) 2002-06-05
BR9509421A (pt) 1997-09-30
US20020183508A1 (en) 2002-12-05
WO1996013590A3 (en) 1996-08-15
WO1996013590A2 (en) 1996-05-09
DE69526973T3 (de) 2010-01-07
CA2201703A1 (en) 1996-05-09
EP1076092A3 (de) 2001-03-28
ES2176342T3 (es) 2002-12-01
AU702436B2 (en) 1999-02-18
US7129337B1 (en) 2006-10-31
ATE218617T1 (de) 2002-06-15
DE69526973T2 (de) 2003-01-02
EP0804584B2 (de) 2008-07-09
JP2005118044A (ja) 2005-05-12
PT804584E (pt) 2002-11-29
JPH10507643A (ja) 1998-07-28
ES2176342T5 (es) 2010-02-09

Similar Documents

Publication Publication Date Title
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
FI946066A0 (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
MX9801715A (es) Secuencia novedosa en el extremo 3' del genoma del virus de la hepatitis c, y su uso en diagnostico y en la preparacion de composiciones terapeuticas.
ID21649A (id) Inhibitor serum protease, terutama virus hepatitis c ns3 protease
ID28224A (id) Virus sindrom perusakan multisistemik paska-pemutusan dari babi
DE59109221D1 (de) HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
FI942369L (fi) Hepatitis-C-virustesti
DE60113139D1 (de) Hcv mosaik antigen zusammensetzung
NO20000514D0 (no) Oligonukleotidprimere for effektiv multipleks deteksjon av Hepatitis C-virus (HCV) og human immunmangelvirus (HIV) og metoder for anvendelse derav
DE60029327D1 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
ATE115964T1 (de) Non-a non-b sequenzen.
ATE389021T1 (de) Rrekombinante proteine eines pakistani-stammes von hepatitis-e-virus, ihre verwendung in diagnotischen verfahren und als impfstoff
IT1270941B (it) Peptidi di hcv e loro usi.